Intermittent Subcutaneous Apomorphine Therapy for ‘Off’ Episodes in Parkinson’s DiseaseA 6-Month Open-Label Study

被引：0
|
作者：
Richard M. Trosch
Dee Silver
Peter B. Bottini
机构：
[1] The Parkinson’s Disease and Movement Disorders Center,
[2] Coastal Neurological Group,undefined
[3] Mylan Laboratories Inc.,undefined
来源：
CNS Drugs | 2008年 / 22卷
关键词：
Apomorphine; Evaluation Visit; Dopamine Receptor Agonist; Motor Complication; Subcutaneous Apomorphine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose: The outpatient follow-up phase of the apomorphine (APO) 303 study assessed the long-term efficacy and safety of intermittent subcutaneous apomorphine for ‘off’ episodes in patients with advanced Parkinson’s disease.
引用
收藏
页码：519 / 527
页数：8
相关论文
共 50 条
  • [31] Comparative bioavailability of apomorphine sublingual film and subcutaneous apomorphine formulations in patients with parkinson's disease and "OFF" episodes: preliminary results
    Agbo, F.
    Isaacson, S.
    Ellenbogen, A.
    Gil, R.
    Bhargava, P.
    Navia, B.
    Blum, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 445 - 445
  • [32] A prospective, 6-month multicenter, open label dose-rising study of the effect of Sarizotan on dyskinesia in Parkinson's disease
    Olanow, CW
    Goetz, C
    Mueller, T
    Nutt, J
    Rascol, O
    Russ, H
    MOVEMENT DISORDERS, 2002, 17 : S326 - S326
  • [33] Continuous, Subcutaneous Apomorphine Infusion for Persistent Motor Fluctuations in Parkinson's Disease: Full results of the AP2-3000 open-label study
    Isaacson, Stuart
    Ceresoli-Borroni, Gianpiera
    Espay, Alberto
    Pahwa, Rajesh
    Agarwal, Pinky
    Shill, Holly
    Hui, Jennifer
    Dashtipour, Khashayar
    Lew, Mark
    Qin, Peibing
    Nasser, Azmi
    LeWitt, Peter
    NEUROLOGY, 2023, 100 (17)
  • [34] Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
    Kassubek, Jan
    Stocchi, Fabrizio
    Martinez, Ernest Balaguer
    Pahwa, Rajesh
    Ondo, William
    Zhang, Yi
    Bowling, Alyssa
    Pappert, Eric
    Isaacson, Stuart
    Wu, Stacy
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [35] Apomorphine therapy for patients with chronic disorders of consciousness: a multimodal open-label study
    Sanz, L.
    Gosseries, O.
    Lejeune, N.
    Bonin, E.
    Panda, R.
    Sala, A.
    Dikenstein, D.
    Farber, N.
    Thibaut, A.
    Laureys, S.
    Gosseries, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 87 - 87
  • [36] Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study
    Miller, Brian J.
    Claxton, Amy
    Du, Yangchun
    Weiden, Peter J.
    Potkin, Steven G.
    SCHIZOPHRENIA RESEARCH, 2019, 208 : 44 - 48
  • [37] LONG-TERM SAFETY AND TOLERABILITY OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A 6-MONTH, OPEN-LABEL STUDY
    Stahl, Steven M.
    Cucchiaro, Josephine
    Simonelli, D.
    Severs, J.
    Loebel, A.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 322 - 322
  • [38] Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
    Christoph U. Correll
    Kenneth S. Koblan
    Seth C. Hopkins
    Yan Li
    Robert Heather Dworak
    Antony Goldman
    npj Schizophrenia, 7
  • [39] Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study
    Ketter, Terence A.
    Amchin, Jess
    Frye, Mark A.
    Gross, Nicholas
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 197 : 51 - 57
  • [40] Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
    Correll, Christoph U.
    Koblan, Kenneth S.
    Hopkins, Seth C.
    Li, Yan
    Dworak, Heather
    Goldman, Robert
    Loebel, Antony
    NPJ SCHIZOPHRENIA, 2021, 7 (01):
12345